The nodal standard uptake value (SUV) as a prognostic factor in head and neck squamous cell cancer

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 7, 2011, Pages 1817-1820

  Demirci, Umut ^a   Coskun, Ugur ^b   Akdemir, U Ozgur ^b   Benekli, Mustafa ^b   Kapucu, Ozlem ^b   Ozkan, Secil ^b   Cakir, Tansel ^b   Baykara, Meltem ^b   Buyukberber, Suleyman ^b  

^a ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Head and neck SCC; standardized uptake value; 18F fluoro D glucose POT CT

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; HEAD AND NECK TUMOR; HUMAN; MALE; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; PROGNOSIS; RETROSPECTIVE STUDY; SCINTISCANNING; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865228362     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Allal AS, Slosman DO, Kebdani T, et al (2004). Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2- deoxy-D-glucose. Int J Radiat Oncol Biol Phys, 59, 1295-300.
2. Bos R, van Der Hoeven JJ, van Der Wall E, et al (2002). Biologic correlates of 18 fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol, 20, 379-87.
3. Burgman P, O'Donoghue JA, Humm JL, Ling CC (2001). Hypoxia-induced increase in FDG uptake in MCF7 cells. J Nucl Med, 42, 170-5.
4. Couture C, Raybaud-Diogene H, Tetu B, et al (2002). p53 and Ki-67 as markers of radioresistance in head and neck carcinoma. Cancer, 94, 713-22.
5. Edge SE, Byrd DR, Compton CC, et al eds (2010). AJCC cancer Staging Manual. 7th ed. New York: Springer.
6. Fleming AJ Jr, Smith SP Jr, Paul CM, et al (2007). Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients. Laryngoscope, 117, 1173-9.
7. Forastiere AA, Goepfert H, Maor M, et al (2003). Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med, 349, 2091-8.
8. Halfpenny W, Hain SF, Biassoni L, et al (2002). FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer, 86, 512-6.
9. Hoshikawa H, Mitani T, Nishiyama Y, et al (2009). Evaluation of the therapeutic effects and recurrence for head and neck cancer after chemoradiotherapy by FDG-PET. Auris Nasus Larynx, 36, 192-8.
10. Inokuchi H, Kodaira T, Tachibana H, et al (2011). Clinical usefulness of [18F] fluoro-2-deoxy-D-glucose uptake in 178 head and-neck cancer patients with nodal metastasis treated with definitive chemoradiotherapy: consideration of its prognostic value and ability to provide guidance for optimal selection of patients for planned neck dissection. Int J Radiat Oncol Biol Phys, 79, 747-55.
11. Jemal A, Siegel R, Xu J, et al (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300.
12. Kee F, Erridge S, Bradbury I, et al (2010). The value of positron emission tomography in patients with non-small cell lung cancer. Eur J Radiol, 73, 50-8.
13. Kim SY, Roh JL, Kim JS, et al (2008). Utility of FDG PET in patients with squamous cell carcinomas of the oral cavity. Eur J Surg Oncol, 34, 208-15.
14. Kresnik E, Mikosch P, Gallowitsch HJ, et al, (2001). Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods. Eur J Nucl Med, 28, 816-21.
15. Minn H, Lapela M, Klemi PJ, et al (1997). Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med, 38, 1907-11.
16. Monnerat C, Faivre S, Temam S, et al (2002). End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Ann Oncol, 13, 995-1006.
17. Murakami R, Uozumi H, Hirai T, et al (2007). Impact of FDG-PET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys, 68, 377-82.
18. Pignon JP, le Maître A, Maillard E, et al (2009). Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol, 92, 4-14.
19. Roh JL, Pae KH, Choi SH, et al (2007). 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography as guidance for primary treatment in patients with advanced-stage resectable squamous cell carcinoma of the larynx and hypopharynx. Eur J Surg Oncol, 33, 790-5.
20. Schinagl DA, Span PN, Oyen WJ, et al (2011). Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study. Eur J Nucl Med Mol Imaging, 2011 Apr 2. [Epub ahead of print]
21. Swisher SG, Erasmus J, Maish M, et al (2004). 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer, 101, 1776-85.
22. Urba S, Wolf G, Eisbruch A, et al (2006). Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol, 24, 593-8.
23. Yao M, Smith RB, Hoffman HT, et al (2009). Clinical significance of postradiotherapy [18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer-a long-term outcome report. Int J Radiat Oncol Biol Phys, 74, 9-14.